Glenmark Pharmaceuticals Gears Up for Q3 Reveal on 30th January; Check Key Expectations Here

Click and Sign Up to Get Live Updates on Q3 Results 

Glenmark Pharmaceuticals’ Q3 results FY26 are scheduled to be announced on 30th January 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.

Glenmark Pharmaceuticals Q3 Results 2026 Preview

• Glenmark Pharmaceuticals’ revenue is expected to be in the range of ₹3,87.55 crore, a 1.35% YoY decrease. 
• Profit After Tax, or PAT, is projected to fall by 1.77% YoY. 
• Glenmark Pharmaceuticals’ EBITDA is expected to fall to ₹477.49 crore. 
• Net profit is ₹347.96 crore, a fall 1.77% YoY 

Glenmark Pharmaceuticals Share Performance 

• Over the past six months, Glenmark Pharmaceuticals’ share price has fallen by 8.95% to ₹538.65.
• Moreover, over the past year, the stock has increased by 12.87%.
• Despite this weak short-term performance, Glenmark Pharmaceuticals’ stock has delivered a financially sound 239.85% return over the past 5 years.
• As of 29th January 2026, the stock traded at ₹538.05 per share.

Key Factors to Watch for Glenmark Pharmaceuticals Q3 Results FY26 

• Revenue & Growth Dynamics: Look for topline growth trends in domestic and international markets, particularly across key geographies like India, Europe and North America.
• Profitability & Margins: Monitor consolidated PAT, EBITDA and margin expansions or contractions versus the prior year/quarter.
• Segment Performance: Evaluate performance of core businesses—formulations, specialty products, generics and newer therapeutic lines—plus contribution from branded markets.
• Regulatory & Operational Developments: Watch for updates on manufacturing site approvals (e.g., USFDA inspections) and supply-chain impacts that can influence future sales.
• Product Pipeline & New Launches: Assess commentary on launches/approvals of key products, including specialty or high-value drugs that can drive medium-term growth.

Final Thoughts

Glenmark Pharmaceuticals will announce its Q3 FY26 results on 30th January 2026. Analysts expect 5.27% YoY revenue growth, a 0.95% fall in PAT, and a 5.99% fall in EBITDA. Glenmark Pharmaceuticals focuses on being a research-led, global pharmaceutical company that develops, manufactures and markets branded, generic and over-the-counter (OTC) medicines across key therapy areas such as respiratory, dermatology, oncology, diabetes and cardiovascular health, while advancing innovative specialty products and novel drug candidates through robust R&D and global commercialization efforts.

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

Recent Articles

Capital Small Finance Bank Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Carborundum Universal Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Capri Global Capital Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Digitide Solutions Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Flair Writing Industries Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

GHCL Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Apar Industries Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Apollo Pipes Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here